ClinicalTrials.gg
Active, not recruitingNCT04874311TRUSTUpdated Jul 24, 2026

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

A Phase 2 interventional study of Bintrafusp alfa and Doxorubicin in Advanced Soft-tissue Sarcoma and Metastatic Soft-tissue Sarcoma, sponsored by Institut Bergonié. Active, not recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Institut Bergonié · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Sarcoma by Institut Bergonié — 6 open to participants now, 9 under way, 1 of them phase 3. Sarcoma · Institut Bergonié.

Planned enrollment
8th of 18
80 · median 69
Started
2022
with 3 others
Phase 2
8 of 22
1 open now
Registered
17th of 22
by date

Among the 22 studies in Sarcoma by Institut Bergonié, this one is the 8th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2022, is one of 8 in phase 2, and was the 17th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

6 of the 22 studies in Sarcoma by Institut Bergonié are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sarcoma by Institut Bergonié, or all of them as a file.
02

Study summary

This study encompasses two multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trials to assess the antitumor activity of bintrafusp alfa in association with doxorubicin

Read the detailed description

This is a two multicenter, prospective, open-labeled, 2-arm, non-comparative randomized (2:1) phase II trials.

Patients satisfying eligibility criteria will first be stratified into 2 strata / subgroups:

  • Soft-tissue sarcoma (STS) patients with an inflamed tumor (i.e. TLS+, defined as presence of mature tertiary lymphoid structures, as per IHC).
  • Soft-tissue sarcoma patients with a cold tumor (i.e. TLS-, defined as absence of mature tertiary lymphoid structures, as per IHC).
  • Note: TLS+ and TLS- account for 20% and 80% of STS patients, respectively.

STS patients with TLS+ will be randomized between arm A (bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance) and arm B (doxorubicin for 6 cycles) with two patients randomized in arm A for one patient randomized in arm B.

STS patients with TLS- will be randomized between arm C (bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance) and arm D (doxorubicin for 6 cycles) with two patients randomized in arm C for one patient randomized in arm D.

03

Conditions studied

  • Advanced Soft-tissue Sarcoma
  • Metastatic Soft-tissue Sarcoma

Keywords

  • tertiary lymphoid structure
  • soft-tissue sarcoma
  • advanced/metastatic
  • immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed soft-tissue sarcoma with unknown translocation (including the following histologies but not limited to undifferentiated pleomorphic sarcomas, dedifferentiated liposaromas or leiomyosarcomas). Diagnosis must be reviewed or confirmed by the RRePS Network (Réseau de référence en pathologie des sarcomes et des viscères) as recommended by the French NCI (Institut National du Cancer, Inca).
  2. or unresectable locally advanced disease,
  3. No previous systemic treatment for advanced/metastatic disease,
  4. For TLS status: available archived FFPE (Formalin-Fixed Paraffin-Embedded) tumor tissue sample or tumor material newly obtained by . Except if TLS analysis have been already performed by Biopathological platform at Bergonié Institute, presence or absence of TLS should be confirmed by central review based on FFPE tumor tissue sample (archived or newly obtained by biopsy for research purpose),
  5. Age ≥ 18 years,
  6. ≤ 1,
  7. > 3 months,
  8. Patients must have defined as per v1.1 with at least one lesion that can be measured in at least one dimension as > 10 mm with spiral CT scan.,
  9. Patient must comply with the collection of tumor biopsies and biomarkers study. Tumors must be accessible for biopsy,
  10. Adequate hematological, renal, metabolic and hepatic function
  11. Female subjects of must have a negative serum pregnancy test within 7 days prior to randomization. Serum or urine pregnancy test must be repeated within 72 hours prior to receiving the first dose of study medication,
  12. Both women and men must agree to use a highly effective method of throughout the treatment period and for at least two months after discontinuation of treatment for women and four months for men.
  13. No prior or concurrent malignant disease diagnosed or treated in the last 3 years except for superficial/non-invasive bladder cancer, or basal or squamous cell carcinoma in situ treated with curative intent; b. endoscopically resected GI cancers limited to the mucosal layer without recurrence in > 1 year,
  14. Recovery to grade ≤ 1 from any adverse event derived from previous treatment (excluding alopecia and vitiligo of any grade and non-painful peripheral neuropathy grade ≤ 2) according to to , version 5.0,
  15. Voluntarily signed and dated written prior to any study specific procedure,
  16. Patients with a social security in compliance with the French law.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with doxorubicin, daunorubicin, epirubicin, idarubicin and/or any other anthracyclines or anthracediones at the maximum cumulative dose or any approved or treatment targeting PD1, or TGFB1,
  2. Known central nervous system (CNS),
  3. Men or women of who are not using an effective method of as previously described; women who are pregnant or breast feeding,
  4. Participation to a study involving a medical or therapeutic intervention in the last 30 days,
  5. Previous enrolment in the present study,
  6. Patient unable to follow and comply with the study procedures because of any geographical, social or psychological reasons,
  7. Known to any involved study drug or any of its formulation components,
  8. Any history of anaphylaxis, or recent, within 5 months, history of uncontrollable asthma,
  9. Individuals deprived of liberty or placed under legal guardianship,
  10. Any of the following cardiac criteria:

    1. Mean resting interval (QTcF) ≥ 470 msec, obtained from three consecutive ECGs,
    2. Any abnormalities in rhythm, conduction or morphology of resting ,
    3. ≤ 50% per v5 by MUGA or echocardiogram
    4. Any factors increasing the risk of QTc prolongation or arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years old or any concomitant medication known to prolong the QT interval,
    5. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, uncontrolled hypertension, congestive heart failure Grade ≥2, ventricular arrhythmias requiring continuous therapy, supraventricular arrhythmias including atrial fibrillation, which are uncontrolled, haemorrhagic or thrombotic stroke, including , cerebral vascular accident/stroke or any other central nervous system bleeding
  11. Active disease that might deteriorate when receiving an immunostimulatory agent:
  12. History of bleeding diathesis or recent major bleeding event ,
  13. Prior organ transplantation including allogenic stem-cell transplantation, except transplants that do not require ,
  14. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection requiring systemic therapy, drug-induced interstitial lung disease or subject has had a history of drug-induced pneumonitis that has required oral or IV , and/or other diseases, which in the opinion of the investigator might impair the subject's tolerance for the study or ability to consistently participate in study procedures,
  15. Active infection including tuberculosis ,
  16. Has known active or ,
  17. Has a known history of infection,
  18. Receipt of within 30 days prior to the first dose of treatment. Note: Patients, if enrolled, should not receive live vaccine within 30 days prior to the first dose of treatment, whilst receiving study treatments and up to 30 days after the last dose. Seasonal flu vaccines that do not contain a live virus are permitted,
  19. Patients with current or history of deep vein thrombosis within 6 months prior to randomization,
  20. Any to for the research,
  21. Any other contraindication to Doxorubicin administration,.
  22. Patients with oral anticoagulation therapy based on Vitamin K antagonist.
  23. Prior mediastinal radiation.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Experimental Arm A: treatment by bintrafusp alfa combined with doxorubicin

    Soft-tissue sarcoma patients with an inflammed tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance

    Drug: Bintrafusp alfa · Drug: Doxorubicin

  • Other
    Standard Arm B: treatment by doxorubicin

    Soft-tissue sarcoma patients with an inflammed tumor will be treated with doxorubicin for 6 cycles

    Drug: Doxorubicin

  • Experimental
    Experimental Arm C: treatment by bintrafusp alfa combined with doxorubicin

    Soft-tissue sarcoma patients with a cold tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance

    Drug: Bintrafusp alfa · Drug: Doxorubicin

  • Other
    Standard Arm D: treatment by doxorubicin

    Soft-tissue sarcoma patients with a cold tumor will be treated with doxorubicin for 6 cycles

    Drug: Doxorubicin

Interventions

  • Bintrafusp alfa will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 2400 mg.

  • Doxorubicin will be administered by intravenous infusion on day 1 every 3 weeks at a fixed dose of 75 mg/m² for a maximum of 6 cycles

06

What researchers measure

Primary outcomes

  1. Assessment of the antitumor activity of combined administration of standard doxorubicin and double immune modulation with Bintrafusp alfa in terms of 6-month progression-free rate, in STS patients with an inflammed tumor

    Antitumor activity will be assessed in terms of 6-month progression-free rate and is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST v1.1.

    Time frame: 6 months

  2. Assessment of the antitumor activity of combined administration of standard doxorubicin and double immune modulation with Bintrafusp alfa in terms of 6-month progression-free rate, in STS patients with a cold tumor

    Antitumor activity will be assessed in terms of 6-month progression-free rate and is defined as the rate of complete or partial response (CR, PR) or stable disease (SD), as per RECIST v1.1.

    Time frame: 6 months

Secondary outcomes

  1. 6-month objective response rate (ORR) independently for patients with an inflammed tumor

    Objective response is defined as complete response (CR) or partial response (PR) as per adapted RECIST v1.1.

    Time frame: 6 months

  2. 6-month objective response rate (ORR) independently for patients with a cold tumor

    Objective response is defined as complete response (CR) or partial response (PR) as per adapted RECIST v1.1.

    Time frame: 6 months

  3. Best overall response for patients with an inflammed tumor

    Best overall response is defined as the best reponse across all time points (RECIST v1.1). The best overall response rate is determined once all the data for the patient is known

    Time frame: throughout the treatment period, an expected average of 6 months

  4. Best overall response for patients with a cold tumor

    Best overall response is defined as the best reponse across all time points (RECIST v1.1). The best overall response rate is determined once all the data for the patient is known

    Time frame: throughout the treatment period, an expected average of 6 months

  5. 1-year progression-free survival for patients with an inflammed tumor

    Progression-free survival is defined as the delay between the date of randomization and the date of progression (as per RECIST v1.1) or death (from any cause), whichever occurs first

    Time frame: 1 year

  6. 1-year progression-free survival for patients with a cold tumor

    Progression-free survival is defined as the delay between the date of randomization and the date of progression (as per RECIST v1.1) or death (from any cause), whichever occurs first

    Time frame: 1 year

  7. 1-year overall survival for patients with an inflammed tumor

    Overall survival is defined as the delay between the date of randomization and the date of death (from any cause)

    Time frame: 1 year

  8. 1-year overall survival for patients with a cold tumor

    Overall survival is defined as the delay between the date of randomization and the date of death (from any cause)

    Time frame: 1 year

  9. Assessment of the antitumor activity of combined administration of standard doxorubicin and double immune modulation with Bintrafusp alfa in terms of immune response, in STS patients with an inflammed tumor

    Immune response is defined following (iRECIST - Seymour et al. 2017).

    Time frame: Throughout the treatment period, an expected average of 6 months

  10. Assessment of the antitumor activity of combined administration of standard doxorubicin and double immune modulation with Bintrafusp alfa in terms of immune response, in STS patients with a cold tumor

    Immune response is defined following (iRECIST - Seymour et al. 2017).

    Time frame: Throughout the treatment period, an expected average of 6 months

  11. Safety profile independently for each population: Common Terminology Criteria for Adverse Event version 5

    Toxicity graded using the Common Terminology Criteria for Adverse Events version 5

    Time frame: Throughout the treatment period, an expected average of 6 months

Other outcomes

  1. Tumor immune cells levels independently for each population

    Levels of immune cells (CD4, CD8, PDL1)in tumor will be measured by immunohistochemistry

    Time frame: baseline, cycle 2 day 1, and progression (each cycle is 21 days)

  2. Blood cytokines levels independently for each population

    Levels of cytokines (tryptophane, interleukine) in blood will be measured by ELISA

    Time frame: baseline, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)

  3. Blood lymphocytes levels independently for each population

    Levels of fixed PBMC (peripheral blood mononucear cells) in blood will be measured by flow cytometry

    Time frame: baseline, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)

  4. Blood kynurenine levels independently for each population

    Levels of kynurenine in blood will be measured by ELISA

    Time frame: baseline, cycle 2 day 1, cycle 3 day 1 and progression (each cycle is 21 days)

07

Study locations

6 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jan 2027, 58 months after the start.

Of 198 non-industry phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 91. This study's planned 58 months is below that.

Counting every sponsor, half of 227 studies reached it within 66 months; a quarter within 43 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 5, 2021
StartActual
Mar 1, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2027
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04874311
Lead sponsor
Institut Bergonié
Responsible party
Sponsor
First posted
May 5, 2021
Start date
Mar 1, 2022
Primary completion
Jan 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bintrafusp alfa

Start the discussion